- Trials with a EudraCT protocol (7,374)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10,738)
7,374 result(s) found.
Displaying page 214 of 369.
EudraCT Number: 2018-002980-25 | Sponsor Protocol Number: PRESERV | Start Date*: 2020-06-12 | |||||||||||
Sponsor Name:OSP.DEGLI INFERMI DI BIELLA | |||||||||||||
Full Title: Randomized, multicenter, open-label study on PREvention of respiratory SEquelae of RSV bronchiolitis in preterm babies (PRESERV) | |||||||||||||
Medical condition: Respiratory sincizial virus (RSV) bronchiolitis | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003853-70 | Sponsor Protocol Number: PNRR-MR1-2022-12375914 | Start Date*: 2023-05-02 | |||||||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||||||||||||
Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi... | |||||||||||||||||||||||
Medical condition: Wolfram syndrome type 1 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005137-37 | Sponsor Protocol Number: POX-MVA-035 | Start Date*: 2013-07-15 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN® smallpox vaccine in children from birth to less than 12 years of age | |||||||||||||
Medical condition: Prevention of smallpox infection in children | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001931-27 | Sponsor Protocol Number: STARS-trial | Start Date*: 2019-02-28 | |||||||||||
Sponsor Name:IRCCS Istituto Giannina Gaslini | |||||||||||||
Full Title: Comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS | |||||||||||||
Medical condition: Juvenile idiopathic arthritis (JIA) is an umbrella term that encompasses a heterogeneous group of disorders characterised by prolonged synovial inflammation that may cause destructive damage to joi... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001235-31 | Sponsor Protocol Number: DEALSZ-2019-001 | Start Date*: 2019-11-26 | |||||||||||
Sponsor Name:Charité – Universitätsmedizin Berlin | |||||||||||||
Full Title: Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930) | |||||||||||||
Medical condition: Lanadelumab in patients with Factor XII-associated cold autoinflammatory syndrome (FACAS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001926-71 | Sponsor Protocol Number: LDX0319 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dompe farmaceutici s.p.a. | |||||||||||||
Full Title: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a l... | |||||||||||||
Medical condition: Recent onset Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) SI (Completed) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003200-14 | Sponsor Protocol Number: JR-141-GS31 | Start Date*: 2022-05-16 | |||||||||||
Sponsor Name:JCR Pharmaceuticals Co., Ltd. | |||||||||||||
Full Title: A Phase III study of JR-141 in Mucopolysaccharidosis type II (Hunter Syndrome) patients. | |||||||||||||
Medical condition: Mucopolysaccharidosis type II | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017349-77 | Sponsor Protocol Number: TIGET-MLD | Start Date*: 2010-03-15 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: A Phase I/II clinical trial of hematopoietic stem cell gene therapy for the treatment of Metachromatic Leukodystrophy | |||||||||||||
Medical condition: metachromatic leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000005-12 | Sponsor Protocol Number: CRCFC-TEICO.SA.2022 | Start Date*: 2024-02-21 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | ||||||||||||||||||
Full Title: An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS | ||||||||||||||||||
Medical condition: cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002955-20 | Sponsor Protocol Number: ADENO-beta | Start Date*: 2023-11-22 | |||||||||||
Sponsor Name:AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO | |||||||||||||
Full Title: Double-blind randomized controlled study versus placebo to evaluate the efficacy of mono-administration of betamethasone in children with symptomatic Adenovirus infection (ADENO-beta). | |||||||||||||
Medical condition: Pediatric patients diagnosed with symptomatic Adenovirus infection. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000097-29 | Sponsor Protocol Number: WA42985 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV... | |||||||||||||
Medical condition: Lupus Nephritis (LN) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003220-32 | Sponsor Protocol Number: EpicStudy | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:IRCCS MATERNO INFANTILE BURLO GAROFOLO | |||||||||||||
Full Title: Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial. | |||||||||||||
Medical condition: Pediatric Inflammatory Bowel Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003559-12 | Sponsor Protocol Number: INCIPIT | Start Date*: 2021-01-27 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | ||||||||||||||||||
Full Title: Prospective, open-label, non-randomized, single-arm, dose titration study to investigate the efficacy and safety of IncobotulinumtoxinA in children deemed to require a total body dose up to 22U/kg ... | ||||||||||||||||||
Medical condition: Multifocal spasticity of the upper and lower limb due to cerebral palsy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003842-18 | Sponsor Protocol Number: OTL-103-4 | Start Date*: 2019-01-08 | |||||||||||
Sponsor Name:Orchard Therapeutics Ltd. | |||||||||||||
Full Title: A Single Arm, Open Label Clinical Study of Haematopoietic Stem Cell Gene Therapy with Cryopreserved Autologous CD34+ Cells Transduced with Lentiviral Vector encoding WAS cDNA in Subjects with Wisko... | |||||||||||||
Medical condition: Wiskott-Aldrich Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2024-000442-10 | Sponsor Protocol Number: A8081056 | Start Date*: 2024-10-11 |
Sponsor Name:Pfizer, Inc | ||
Full Title: CRIZOTINIB (XALKORI(REGISTERED)) EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADULT OR PEDIATRIC PATIENTS WITH SOLID OR HEMATOLOGIC MALIGNANCIES THAT HARBOR A CRIZOTINIB-SENSITIVE MOLECULAR ALTERA... | ||
Medical condition: Solid tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-002191-41 | Sponsor Protocol Number: AIDIT | Start Date*: Information not available in EudraCT |
Sponsor Name:Uppsala University | ||
Full Title: Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes | ||
Medical condition: Type 1 diabetes | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005416-42 | Sponsor Protocol Number: KF001 | Start Date*: 2015-05-08 | |||||||||||
Sponsor Name:Uppsala University. Department of Women's and children's health | |||||||||||||
Full Title: Clondine in repeated doses for children in pain - a farmacokinetic study | |||||||||||||
Medical condition: Pain in children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2024-000382-25 | Sponsor Protocol Number: SCY-078-120 | Start Date*: 2024-09-25 | |||||||||||
Sponsor Name:SCYNEXIS, Inc. | |||||||||||||
Full Title: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Ibrexafungerp (SCY-078) in Adolescent Female Subjects | |||||||||||||
Medical condition: Vulvovaginal candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003445-37 | Sponsor Protocol Number: ELPIDA-ALLOCART-01 | Start Date*: 2021-09-30 | |||||||||||
Sponsor Name:Aghia Sophia Children’s Hospital | |||||||||||||
Full Title: A Phase 2 Study of the Efficacy and Safety of a Dose of Donor-Derived CD19-targeted CAR T cells for children and young adults (up to 39 years old) with recurrent or persistent CD19 (+) Acute Leukem... | |||||||||||||
Medical condition: Relapsed b Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002800-15 | Sponsor Protocol Number: 2012_67 | Start Date*: 2015-10-13 | |||||||||||
Sponsor Name:Centre Hospitalier Régional Universitaire Lille | |||||||||||||
Full Title: Efficacy of Rapamycine (Sirolimus) in poor prognosis cervifo-facial lymphatic malformations | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
